Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Long-Term Deferred Tax: 2022-2023

  • Bicycle Therapeutics' Long-Term Deferred Tax rose 33.47% to $88.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $88.6 million, marking a year-over-year increase of 33.47%. This contributed to the annual value of $88.6 million for FY2023, which is 33.47% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Long-Term Deferred Tax stood at $88.6 million for Q4 2023, which was up 33.47% from $66.3 million recorded in Q4 2022.
  • Over the past 5 years, Bicycle Therapeutics' Long-Term Deferred Tax peaked at $88.6 million during Q4 2023, and registered a low of $66.3 million during Q4 2022.
  • For the 2-year period, Bicycle Therapeutics' Long-Term Deferred Tax averaged around $77.5 million, with its median value being $77.5 million (2022).
  • Data for Bicycle Therapeutics' Long-Term Deferred Tax shows a peak YoY surged of 33.47% (in 2023) over the last 5 years.
  • Bicycle Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $66.3 million in 2022, then surged by 33.47% to $88.6 million in 2023.